Interventions du FILO à l'ASH 2024 dans le domaine de la LAM

VEN-AZA ?

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Poster présenté par Jules HIGUÉ

Number: 58
Presenter: Jules Higué
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies
Time and Location: 7 Déc 2024 9:30-11:00

Etude ?

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Poster présenté par Régis PEFFAULT DE LATOUR

Number: 3483
Presenter: Régis Peffault De Latour
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Time and Location: 8 Déc 2024 18:00-20:00

Etude ?

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Poster présenté par Edouard FORCADE

Number: 4909
Presenter: Edouard FORCADE
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Time and Location: 9 Déc 2024 18:00-20:00

 BIG-1

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Communication orale présentée par Adriana PLESA

Result Type: Oral
Number: 226
Presenter: Adriana Plesa
Program: Oral and Poster Abstracts
Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond
Time and Location: 7 Déc 2024 14:45